Dr Mukta Krane and colleagues evaluated the influence of infliximab on perioperative outcomes in patients undergoing elective laparoscopic resection for Inflammatory Bowel Disease (IBD).
The research team performed a retrospective analysis of a prospectively collected, institutional review board-approved database.
The team compared patients undergoing laparoscopic resection on preoperative infliximab with patients who did not receive infliximab.
The short-term and long-term morbidity and mortality rates were assessed.
The research team found that elective laparoscopic resection for IBD was performed on 518 patients from 2004 through 2011.
The team reported that 142 patients were treated with infliximab preoperatively.
Both groups had similar demographics, type and severity of IBD, comorbidities, and type of surgery.
The team of doctors found that a significantly higher number of patients in the infliximab group had been on aggressive medical therapy to control symptoms of IBD during the month preceding surgery, including steroids and immunosuppressor.
Operative time and blood loss were similar.
|The intraoperative complication rate was 2% in both groups|
|Diseases of the Colon & Rectum|
The researchers noted that the intraoperative complication rate was 2% in both groups.
No significant differences were observed in terms of the conversion rate to laparotomy, overall 30-day postoperative morbidity, or mortality.
The team of doctors observed that the rates of anastomotic leak, infections, and thrombotic complications were similar.
Subgroup analyses confirmed similar rates of overall, infectious, and thrombotic complications regardless of whether patients had ulcerative colitis or Crohn’s disease.
Dr Krane's team commented, " Infliximab is not associated with increased rates of postoperative complications after laparoscopic resection."